Login to Your Account

Paging 'new era' in CD, UC therapy

New oral Protagonists due to transform IBD's plotline; book closing on anti-TNFs?

By Randy Osborne
Staff Writer

Thursday, March 15, 2018

The surprise thumbs-down recently by the FDA for Celgene Corp.'s ozanimod to treat relapsing multiple sclerosis (MS) echoed the disappointment last year with mongersen (GED-0301) for Crohn's disease (CD), but apparently didn't affect late-stage work with the former compound in ulcerative colitis (UC) and CD.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription